Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 14/20 | 1.00 |
| ▸ | SHBG | P04278 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.80 |
| ▸ | AR | P10275 | 3/20 | 0.77 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.74 |
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.65 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.65 |
| ▸ | PGR | P06401 | 2/20 | 0.65 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | SNCA | P37840 | 2/20 | 0.65 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.65 |
| ▸ | CYP51A1 | Q16850 | 2/20 | 0.65 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.65 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6006777 | 1.00 | CYP19A1 (1.00) | CYP19A1SHBGCYP3A4ARSERPINA6 | |
| SCHEMBL11524096 | 1.00 | CYP19A1 (1.00) | CYP19A1SHBGCYP3A4ARSERPINA6 | |
| SCHEMBL5021333 | 1.00 | CYP19A1 (1.00) | CYP19A1SHBGCYP3A4ARSERPINA6 | |
| SCHEMBL10273241 | 1.00 | CYP19A1 (1.00) | CYP19A1SHBGCYP3A4ARSERPINA6 | |
| 6Beta-Hydroxytestosterone SCHEMBL135030 | 0.89 | CYP3A4 (1.00) | CYP19A1SHBGCYP3A4ARSERPINA6 | |
| 6Beta-Hydroxytestosterone SCHEMBL3278189 | 0.89 | CYP3A4 (1.00) | CYP19A1SHBGCYP3A4ARSERPINA6 | |
| 6Beta-Hydroxytestosterone SCHEMBL14067596 | 0.89 | CYP3A4 (1.00) | CYP19A1SHBGCYP3A4ARSERPINA6 | |
| 6Beta-Hydroxytestosterone SCHEMBL127408 | 0.89 | CYP3A4 (1.00) | CYP19A1SHBGCYP3A4ARSERPINA6 | |
| 6Beta-Hydroxytestosterone SCHEMBL13752809 | 0.89 | CYP3A4 (1.00) | CYP19A1SHBGCYP3A4ARSERPINA6 | |
| 6Beta-Hydroxytestosterone SCHEMBL28056047 | 0.89 | CYP3A4 (1.00) | CYP19A1SHBGCYP3A4ARSERPINA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003068314-A1 | PULMONARY ADMINISTRATION OF 6-ALPHA-ALKYLATED TESTOSTERONE DERIVATIVES FOR ANDROGEN REPLACEMENT THERAPY | PANTARHEI BIOSCIENCE B.V. (NL) | 2003-08-21 | — | — | WO | claimed |
| EP-0941039-A4 | TRANSDERMAL ADMINISTRATION OF MENT | POPULATION COUNCIL INC (US) | 2006-06-21 | — | — | EP | disclosed |
| US-7018648-B2 | Transdermal device for administering testosterone or one of the derivatives thereof | PIERRE FABRE MEDICAMENT (FR) | 2006-03-28 | — | — | US | disclosed |
| US-20050256051-A1 | Nuclear receptor-mediated introduction of a PNA into cell nuclei | THE POPULATION COUNCIL, INC. (US) | 2005-11-17 | — | — | US | disclosed |
| US-20050100586-A1 | Transdermal device for administering testosterone or one of the derivatives thereof | PIERRE FABRE MEDICAMENT (FR) | 2005-05-12 | — | — | US | disclosed |
| EP-1392366-A4 | NUCLEAR RECEPTOR-MEDIATED INTRODUCTION OF A PNA INTO CELL NUCLEI | POPULATION COUNCIL INC (US) | 2005-01-19 | — | — | EP | disclosed |
| EP-0966288-A4 | ANDROGEN AS A MALE CONTRACEPTIVE AND NON-CONTRACEPTIVE ANDROGEN REPLACEMENT | POPULATION COUNCIL INC (US) | 2004-11-10 | — | — | EP | disclosed |
| EP-1178806-B1 | TRANSDERMAL DEVICE FOR THE APPLICATION OF TESTOSTERONE OR ONE OF THE DERIVATIVES THEREOF | PF MEDICAMENT (FR) | 2004-09-01 | — | — | EP | disclosed |
| US-6767902-B2 | Androgen as a male contraceptive and non-contraceptive androgen replacement | THE POPULATION COUNCIL, INC. | 2004-07-27 | — | — | US | disclosed |
| US-20040126418-A1 | Transdermal administration of MENT | THE POPULATION COUNCIL, INC. | 2004-07-01 | — | — | US | disclosed |
| US-20020012694-A1 | TRANSDERMAL ADMINISTRATION OF MENT | POPULATION COUNCIL, INC., THE, A CORP. OF NY | 2002-01-31 | — | — | US | disclosed |
| EP-0966288-A1 | ANDROGEN AS A MALE CONTRACEPTIVE AND NON-CONTRACEPTIVE ANDROGEN REPLACEMENT | THE POPULATION COUNCIL, INC. (US) | 1999-12-29 | — | — | EP | disclosed |
| EP-0941039-A1 | TRANSDERMAL ADMINISTRATION OF MENT | THE POPULATION COUNCIL, INC. (US) | 1999-09-15 | — | — | EP | disclosed |
| WO-1999013883-A1 | ANDROGEN AS A MALE CONTRACEPTIVE AND NON-CONTRACEPTIVE ANDROGEN REPLACEMENT | THE POPULATION COUNCIL, INC. (US) | 1999-03-25 | — | — | WO | disclosed |
| WO-1999013812-A1 | TRANSDERMAL ADMINISTRATION OF MENT | THE POPULATION COUNCIL, INC. (US) | 1999-03-25 | — | — | WO | disclosed |
| EP-0510167-B1 | NOVEL STEROIDAL ORGANIC SUBSTANCE CRYSTALLIZATION METHOD AND COMPOUNDS THEREBY OBTAINED | THERAMEX (MC) | 1995-08-23 | — | — | EP | disclosed |
| US-5342834-A | Administering testosterone derivatives | THE POPULATION COUNCIL, INC. (US) | 1994-08-30 | — | — | US | disclosed |
| US-5266712-A | Process for crystallizing the organic substances from steroidal origin and the thus obtained compounds | LABORATOIRE THERAMEX S.A. (MC) | 1993-11-30 | — | — | US | disclosed |
| WO-1992008730-A1 | NOVEL STEROIDAL ORGANIC SUBSTANCE CRYSTALLIZATION METHOD AND COMPOUNDS THEREBY OBTAINED | LABORATOIRE THERAMEX S.A. (MC) | 1992-05-29 | — | — | WO | disclosed |
| US-4160027-A | OXYTOCICS, 4A,5A-EPOXY-2A-CYANO-3-OXOSTEROIDES, STEROIDO(2,3-O)ISOOXAZOLES | STERLING DRUG INC. (US) | 1979-07-03 | — | — | US | disclosed |